Methylphenidate in Childhood Apraxia of Speech

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

March 14, 2022

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions
Childhood Apraxia of Speech
Interventions
DRUG

Methylphenidate Hydrochloride

Participants will receive twice daily doses of Methylphenidate Hydrochloride four hours apart. There will be three dosage schedules, determined based on three weight ranges (20-30kg; 30-40kg; ≥40kg). For children weighing 20-30kg, the maximum daily dose will be 20mg. For children weighing 30-40kg, the maximum daily dose will be 30mg. For children weighing ≥40kg, the maximum daily dose will be 40mg.

DRUG

Placebo

Participants will receive twice daily doses of placebo capsules. Gelatine placebo capsules will contain hypromellose, an inert substance.

Trial Locations (1)

3052

Murdoch Children's Research Institute, Parkville

All Listed Sponsors
lead

Murdoch Childrens Research Institute

OTHER